Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received additional indication approval from the National Medical Products Administration (NMPA) for its generic version of Abraxis BioScience’s Abraxane (paclitaxel, albumin-bound). The drug is now approved for use in combination with gemcitabine to treat first-line metastatic pancreatic cancer in China.
Abraxane, initially approved in the U.S. in 2005, has since gained registration in the European Union, Japan, and other countries and regions. Hengrui Med’s version of the anti-tubulin drug was first granted approval in China in August 2018 for the treatment of metastatic breast cancer in patients who have failed chemotherapy or experienced relapse within six months after adjuvant chemotherapy.- Flcube.com
